153 related articles for article (PubMed ID: 14651215)
1. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
Kim TW; Kang HJ; Ahn JH; Lee K; Chang HM; Kang YK; Lee JS
Acta Oncol; 2002; 41(7-8):689-94. PubMed ID: 14651215
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
4. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Feliu J; Sáenz JG; Jaráiz AR; Castañón C; Cruz M; Fonseca E; Lomas M; Castro J; Jara C; Casado E; León A; Barón MG
Cancer Chemother Pharmacol; 2006 Oct; 58(4):419-26. PubMed ID: 16404636
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
9. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
[TBL] [Abstract][Full Text] [Related]
11. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
[TBL] [Abstract][Full Text] [Related]
12. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
Tanno S; Nakano Y; Osanai M; Koizumi K; Izawa T; Habiro A; Mizukami Y; Yanagawa N; Fujii T; Okumura T; Kohgo Y
Chemotherapy; 2006; 52(2):98-102. PubMed ID: 16567941
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Mani S; Kugler JW; Sciortino DF; Garcia JC; Ansari RH; Humerickhouse R; Michelassi F; Posner MC; Shulman KL; Schilsky RL; List M; Vokes EE; Benner S
Ann Oncol; 1998 Sep; 9(9):1035-7. PubMed ID: 9818081
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
[TBL] [Abstract][Full Text] [Related]
17. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Childs HA; Spencer SA; Raben D; Bonner JA; Newsome J; Robert F
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):939-44. PubMed ID: 10863063
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]